AMRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMRX is a good buy right now for a beginner long-term investor with $50,000-$100,000 available, but only as a moderate conviction entry rather than a full aggressive bet. The stock has a constructive technical trend, supportive analyst sentiment, and a favorable options setup, while the main downside is that near-term earnings quality and forward sales growth look mixed. Because the user is unwilling to wait for a perfect entry, the current price is acceptable for starting a position.
AMRX shows a bullish technical setup overall. MACD is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. The stock closed at 13.68, just below resistance at R1 13.639 and near the pivot at 13.068, suggesting it is trading in a relatively strong zone. However, RSI_6 at 80.53 is overbought, so the stock is extended in the short term even though the broader trend remains positive. The trend pattern data also suggests favorable near-term follow-through.
["UBS initiated coverage with a Buy rating and $19 target, citing an attractive entry point and best-in-group growth profile.", "Goldman Sachs and Truist both raised price targets to $17 and maintained Buy ratings after solid Q4 results and strong FY26 EBITDA outlook.", "JPMorgan raised its target to $18 and kept an Overweight rating.", "Revenue in 2025/Q4 grew 11.47% YoY, showing continued top-line expansion.", "Gross margin improved to 36.5%, supporting better operating efficiency.", "Bullish moving averages and positive MACD indicate the trend is still intact.", "Options sentiment is constructive with a low put-call ratio.", "No recent negative congress, insider, or hedge fund activity was reported."]
["News commentary says Amneal is projected to have only 2.4% sales growth over the next 12 months, implying slower forward demand.", "Net income fell sharply year over year in the latest quarter, and EPS also declined materially.", "RSI is overbought, so the stock may pause or consolidate before adding more gains.", "There is no valuation data provided to confirm the stock is still cheap after the recent move.", "Hedge funds and insiders are neutral, so there is no strong accumulation signal from smart money."]
In 2025/Q4, Amneal posted revenue of 814.3M, up 11.47% YoY, which is a solid growth signal. Gross margin improved to 36.5%, also positive. The main weakness is profitability: net income dropped to 35.1M and EPS fell to 0.11, both down sharply year over year. For a long-term investor, the quarter shows improving scale and margins, but earnings quality remains uneven.
Analyst sentiment is clearly positive and improving. UBS initiated Buy at $19, Goldman Sachs raised the target to $17 with Buy, Truist raised the target to $17 with Buy, and JPMorgan increased its target to $18 with Overweight. The Wall Street pros view is favorable: bulls like Amneal’s specialty growth, Parkinson’s franchise, and EBITDA improvement. The main con from the Street is slower expected revenue growth and some softness in GRx/distribution topline guidance.
